<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="28680">Cytarabine</z:chebi> ocfosfate (SPAC) was administered orally to 19 patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>SPAC was administered at doses of 200-300 mg/day for more than 14 days with granulocyte colony-stimulating factor (G-CSF) </plain></SENT>
<SENT sid="2" pm="."><plain>Four of the 12 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 1 of the 7 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> achieved complete remission (CR) after one cycle of SPAC treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Especially, 3 of the 6 patients with newly diagnosed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> achieved CR </plain></SENT>
<SENT sid="4" pm="."><plain>Major side effects of SPAC were <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> and tolerable <z:e sem="disease" ids="C0017178" disease_type="Disease or Syndrome" abbrv="">gastrointestinal disorders</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The treatment with SPAC is a therapeutic option in elderly patients or patients with organ failure </plain></SENT>
</text></document>